Objective: The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).
Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19.
Results: pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p>0.001). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers.
Conclusion: Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629510 | PMC |
| http://dx.doi.org/10.1016/j.msard.2021.103435 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis.
Front Pharmacol
September 2024
Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Dresden, Technical University of Dresden, Dresden, Germany.
Background: Siponimod, a second-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, represents an important therapeutic choice for active secondary progressive multiple sclerosis (SPMS). Besides the beneficial immunomodulatory effects, siponimod impacts cardiovascular function through S1PR1 modulation. Short-term vagomimetic effects on cardiac activity have proved to be mitigated by dose titration.
View Article and Find Full Text PDFReal-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
Mult Scler
April 2024
Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK.
Background: Siponimod-related lymphopenia in real-world clinical practice has implications for dose adjustment and infection risk.
Objective: To characterise siponimod-related lymphopenia in people with secondary progressive multiple sclerosis (pwSPMS).
Methods: This is a retrospective cohort of 188 pwSPMS.
Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.
Mult Scler J Exp Transl Clin
January 2024
Novartis Pharmaceuticals Australia, Macquarie Park, NSW, Australia.
Background: Siponimod is approved for use in people with secondary progressive multiple sclerosis (pwSPMS). An integrated digital platform, MSGo, was developed for pwSPMS and clinicians to help navigate the multiple steps of the pre-siponimod work-up.
Objective: To explore real-world onboarding experiences of siponimod amongst pwSPMS in Australia.
Short- and long-term effects of siponimod on autonomic nervous system in secondary progressive multiple sclerosis.
Mult Scler Relat Disord
August 2022
School of Medicine, University of Zagreb, Zagreb, Croatia; Faculty of Electrical Engineering and Computing, University of Zagreb, Zagreb, Croatia.
Objectives: The aim of this study was to investigate the short- and long-term effects of siponimod on autonomic nervous system (ANS) function, in people with secondary progressive multiple sclerosis (pwSPMS) METHODS: The following ANS tests were performed in 26 pwSPMS: a 10 min supine resting position, Valsalva maneuver, deep breathing test and a 10 min tilt-up table test. Heart rate variability (HRV) was performed for the 10 min in supine resting position (M0) and for a 3 h period after siponimod treatment initiation (M0). All ANS tests were repeated after at least 6 months of treatment with siponimod (M6).
View Article and Find Full Text PDFHumoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod.
Mult Scler Relat Disord
January 2022
Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia. Electronic address:
Objective: The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).
Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19.
Results: pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!